7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Gut Health

Is the Virus Really Gone? The Follow-Up Test After Hepatitis C Treatment Explained

24 min read
Is the Virus Really Gone? The Follow-Up Test After Hepatitis C Treatment Explained

Key Takeaways

  • The follow-up test after hepatitis C treatment is an HCV RNA (viral load) test drawn about 12 weeks after the final dose; an undetectable result at that point is called SVR12.
  • A hepatitis C antibody test stays positive for life after any infection and cannot tell you whether treatment worked; only the RNA test can.
  • Direct-acting antiviral courses typically last 8 to 12 weeks, and the World Health Organization reports that more than 95% of treated people reach a sustained virologic response.
  • Relapse, when it occurs, almost always becomes detectable within the first 12 weeks after treatment, which is why that interval was chosen for the key test.
  • An undetectable virus means you cannot pass hepatitis C to others, but it leaves no immunity, so reinfection from a new blood exposure remains possible.
  • People who had cirrhosis before treatment keep a reduced but lasting risk of liver cancer and are offered ongoing surveillance even after a clear RNA result.
Quick Answer

The follow-up test after hepatitis C treatment is a blood test for the virus's genetic material (HCV RNA), usually taken about 12 weeks after the last tablet. An undetectable result at that point is called a sustained virologic response, or SVR12, and clinicians treat it as the standard sign that the infection has cleared. The antibody test stays positive for life and cannot confirm this.

The last tablet comes out of the blister pack on an ordinary morning. No ceremony, no scan, no stitches. Just a glass of water and a strange silence where a daily habit used to be. Then the nurse says the sentence that lands harder than any side effect did: come back in twelve weeks and we will see.

That gap is where most of the worry lives. People read their hepatitis C treatment results on a patient portal at midnight and try to decode phrases like “target not detected” or “below the limit of quantification.” Some panic when a different line on the same report still says “antibody reactive.” Others assume that an undetectable virus means a liver restored to factory settings.

This piece walks through what the follow-up test actually measures, why the waiting period exists, what the numbers do and do not tell you, and which questions are worth bringing to the clinic.

What do hepatitis C treatment results actually measure?

Hepatitis C is caused by a virus that lives mainly in liver cells and copies itself using its own genetic code, a strand of RNA. The modern treatments, called direct-acting antivirals (medicines that block specific proteins the virus needs to reproduce), do not attack the liver or boost the immune system in some general way. They jam the copying machinery. Within days of starting, the amount of virus in the blood typically falls steeply; by the end of a course, most people have none that a laboratory can find (NHS, Mayo Clinic).

The test that tracks this is the HCV RNA test, sometimes labelled a PCR or viral load. It hunts for fragments of the virus’s genetic material in a blood sample. A result reported as “not detected” means the laboratory looked and found nothing above its detection threshold. A result with a number attached means virus was present and the number estimates how much.

So when clinicians talk about hepatitis C treatment results, they almost always mean one specific RNA result taken at one specific moment: roughly 12 weeks after the final dose. Everything else on the report is context.

Why not simply test on the last day of treatment? Because an undetectable reading while medicine is still circulating proves only that the drugs are suppressing the virus, not that the virus is gone. A small reservoir can survive in a handful of cells and start copying again once the pressure lifts. Waiting lets the body show whether that reservoir existed. The RNA test, in other words, is less a snapshot of the treatment and more a snapshot of what happens after the treatment stops.

What is SVR12, and why does the follow-up wait 12 weeks?

SVR stands for sustained virologic response: no detectable hepatitis C RNA in the blood a set period after treatment has ended. The number after it tells you how long that period was. SVR12 means 12 weeks; SVR24 means 24 weeks. Mainstream guidance now uses SVR12 as the standard marker because, in the large trials that led to direct-acting antivirals, almost everyone who was undetectable at 12 weeks remained undetectable at 24 weeks and beyond (Mayo Clinic, NHS).

Doctor consulting with male patient, reviewing medical document: What is SVR12, and why does the follow-up wait 12 weeks?

Twelve weeks is not an arbitrary round number. Relapse, when it happens, tends to show up early, usually within the first few weeks after the drugs leave the body, because any surviving virus copies itself quickly once unopposed. By the three-month mark, a relapse has almost always declared itself as a measurable viral load. A clear result at that point therefore carries real weight.

The World Health Organization, in its hepatitis C fact sheet, reports that direct-acting antiviral treatment leads more than 95% of treated people to reach this sustained response. That is a population figure from pooled evidence, not a guarantee for any one individual, and it varies somewhat with prior treatment history and the state of the liver. Your clinician will interpret your own result in light of those factors.

Some services still request a second RNA test at 24 weeks, or a year later, particularly for people with cirrhosis (advanced scarring of the liver) or with ongoing risk of a new exposure. That extra test is a belt-and-braces check, not a sign that the first result was doubted. If your team schedules one, it is worth asking what specifically they are watching for, because the reasoning differs from person to person.

Why your hepatitis C antibody test stays positive after treatment

The single most common source of alarm after treatment is a line on the lab report that still reads “HCV antibody: reactive.” People see it and conclude the virus is back. It is not. The antibody test and the RNA test answer two completely different questions.

An antibody is a protein the immune system makes in response to an infection. Once your body has produced hepatitis C antibodies, it keeps making them, usually for life, whether or not the virus itself is still present. The antibody test therefore tells you that you were exposed at some point. It cannot tell you whether the infection is current, cleared on its own, or cleared by treatment (CDC, MedlinePlus).

The RNA test is the one that looks for the actual virus. That is why standard testing pathways run an RNA test automatically after any positive antibody result, and why the follow-up after treatment is an RNA test only. Ordering an antibody test after treatment adds nothing except confusion.

This matters in practical life. If you give blood for an unrelated screening, apply for certain types of insurance, or move to a new clinic, the antibody result will show up again. Carrying a copy of your post-treatment RNA result, and knowing the phrase “sustained virologic response,” saves repeated explanations. Some people ask their clinician to add a short note to the record for exactly this reason.

One more wrinkle: antibodies from a past hepatitis C infection do not protect you from a new one. Unlike many viruses, hepatitis C does not leave useful immunity behind. That is why the conversation about avoiding re-exposure continues after treatment, which we come to later.

How long does hep C treatment take, and when does the follow-up clock start?

Most people now take direct-acting antiviral tablets once a day for 8 to 12 weeks, according to the NHS treatment overview; some courses run longer, up to 24 weeks, where the liver is already heavily scarred or earlier treatment did not work (WHO). The length is chosen by the prescribing team based on the virus’s genotype (its genetic strain), the state of the liver, and prior treatment history. None of those choices are things to adjust on your own.

Doctor consulting with patient in medical office: How long does hep C treatment take, and when does the follow-up clock star

The follow-up clock starts on the day after your final tablet. Count 12 weeks forward from there and you have the earliest date at which an SVR12 result is meaningful. Finishing early, skipping days, or stopping because you felt fine shifts that date and, more importantly, raises the chance of a surviving reservoir of virus. If something interrupts your course, the right move is to tell the prescriber the same day so they can advise, not to quietly extend or compress it.

Many clinics also test during treatment, often at around four weeks, to confirm the viral load is dropping as expected and to check that the tablets are being absorbed. A detectable reading at that stage is not a verdict. Some people clear more slowly, and the key result remains the one taken after the course ends.

Side effects with current regimens are generally mild compared with the older interferon-based treatments, which involved injections and months of flu-like symptoms. Tiredness, headache and nausea are the ones most commonly reported (Mayo Clinic). The practical upshot is that the treatment phase, for many people, is less demanding than the waiting phase that follows it. Knowing that in advance can make the twelve weeks feel less like limbo.

Who is usually tested at 12 weeks, and who is asked to wait or test again?

Nearly everyone who completes a course of direct-acting antivirals is offered an RNA test at the 12-week point. That is the default. The variations lie in who gets additional tests and who may be asked to wait before the result is treated as final.

People with cirrhosis form the largest group with extra follow-up. The virus may be gone, but scarred tissue carries its own risks, including a lifelong, reduced but not zero chance of liver cancer. For them, the SVR12 result is one milestone in a longer monitoring plan that includes periodic imaging and blood tests arranged by a liver specialist (Mayo Clinic, Cleveland Clinic).

People whose treatment was interrupted, who missed a significant number of doses, or who were previously treated without success may be asked to test again at 24 weeks. The reasoning is caution: the odds of late relapse are low, but the consequences of missing one are not trivial.

Anyone with an ongoing risk of new exposure, for example people who inject drugs or men who have sex with men with HIV, is usually offered RNA testing at intervals after treatment, not because the first course is doubted but because a fresh infection would look identical on the test. Pregnancy, kidney disease and co-infection with hepatitis B each prompt their own adjustments to timing and to what else is monitored.

The people asked to wait are usually those whose 12-week sample is drawn a little early, or whose result lands near the detection threshold and needs repeating with a more sensitive assay. A “please come back in a few weeks” message in that situation is a technical request, not a bad sign. If you are unsure which group you fall into, ask directly. The schedule is built around your circumstances, and the team can explain why yours looks the way it does.

What the weeks after your last tablet usually look like

The first week after finishing is often anticlimactic. The medicine clears from the body over several days; any mild side effects fade with it. Some people notice energy returning, though it is hard to separate the effect of a cleared virus from the relief of no longer being on treatment. Both are real.

Weeks two to six are the period when relapse, if it is going to happen, most often becomes detectable. You will feel nothing either way. Hepatitis C is notorious for being silent; most chronic infections cause no symptoms for years (WHO, CDC). That silence cuts both ways: the absence of symptoms after treatment is reassuring emotionally but proves nothing medically. Only the blood test does.

Around week twelve comes the appointment. Blood is drawn, usually from the arm, and sent for RNA testing. Results can take several days to a couple of weeks depending on the laboratory. Many clinics phone or message; others wait for a face-to-face review. Ask in advance how you will hear.

Liver enzyme levels, the proteins measured on a standard liver blood panel, commonly fall toward the normal range once the virus is gone, sometimes within weeks. A persistently raised level after an undetectable RNA result points the clinician toward other causes, such as alcohol, a fatty liver or a medication effect, and is worth investigating rather than ignoring.

Beyond twelve weeks, the pattern depends on your liver. Someone with no significant scarring may be discharged from specialist follow-up after the SVR12 result, with a note to their regular doctor. Someone with cirrhosis will be scheduled for ongoing surveillance. Either way, the day of the result is a sensible moment to ask what the plan is from here and who is responsible for it.

Reading your hepatitis C treatment results: a plain-language table

Laboratory reports are written for laboratories. The table below translates the lines that most often confuse people, with the caveat that your own clinician’s interpretation always takes priority, since reference ranges and wording differ between labs.

What the report says What it usually means What it does not mean
HCV antibody: reactive or positive You were exposed to hepatitis C at some point and your body made antibodies That the virus is currently present; antibodies persist after clearance
HCV RNA: not detected (12 weeks after treatment) Sustained virologic response, SVR12; no virus found above the test threshold That liver scarring has reversed or that you are immune to reinfection
HCV RNA: detected, below limit of quantification A trace of viral material was found but too little to count; often repeated Confirmed relapse; the clinician will decide whether to retest
HCV RNA: detected with a number (viral load) Virus is present and copying; after treatment this suggests relapse or new infection How sick you are; viral load does not measure liver damage
Genotype: 1a, 1b, 2, 3 and so on The genetic strain of the virus, used to choose treatment A grade of severity; strain does not equal prognosis on its own
ALT or AST: raised Liver cells are releasing enzymes, a sign of inflammation from any cause That hepatitis C is back; many other things raise these values

Two phrases deserve special mention. “Target not detected” and “not detected” are the wording most laboratories use for an undetectable result; they are the same thing. “Detected, not quantifiable” sits in a gray zone and is the single most frequently misread line on a post-treatment report. It calls for a conversation, not a conclusion.

What is the main cause of hep C, and how contagious is hep C once the virus is undetectable?

Hepatitis C has one cause: the hepatitis C virus, which spreads when blood carrying it enters another person’s bloodstream. Globally, the World Health Organization identifies unsafe injection practices in healthcare, inadequate sterilization of medical equipment, unscreened blood transfusions and sharing of drug-injecting equipment as the main routes. In the United States, sharing needles or other equipment to inject drugs is the most common route today, according to the CDC. Transmission from a pregnant parent to the baby occurs in a minority of cases, which the CDC puts at roughly 6% of births to people with the infection.

How contagious is hep C in daily life? Far less than many people assume. The virus is not spread by hugging, kissing, coughing, sneezing, sharing food or water, sharing utensils, or breastfeeding, unless nipples are cracked and bleeding (CDC, Cleveland Clinic). Sexual transmission is possible but uncommon between long-term monogamous partners; the risk rises with multiple partners, with sexually transmitted infections that cause sores, and with HIV. Sharing razors, toothbrushes or nail clippers, items that can carry small amounts of blood, is the household route that does occasionally matter.

Once your RNA test is undetectable, there is no virus in your blood to pass on. A person with a sustained virologic response is not infectious to others through any route. That is one of the quieter benefits of treatment and one that people sometimes do not hear clearly at the clinic.

The flip side is that your own susceptibility does not change. Because the infection leaves no protective immunity, the same exposures that caused the first infection can cause a second. Keeping injecting equipment personal, using condoms where risk is present, and avoiding shared sharps remain relevant after treatment exactly as they did before it.

Can hep C come back? Relapse versus hep c reinfection after treatment

Two very different events get lumped together under “it came back,” and the distinction changes what happens next.

Relapse means the original infection was suppressed but not eliminated; a small reservoir of virus survived and began copying again once the medicine stopped. It almost always becomes detectable within the first 12 weeks, which is the whole reason the SVR12 test exists. With current direct-acting antivirals, relapse is uncommon, and when it happens the prescribing team can usually offer a different regimen chosen on the basis of resistance testing (Mayo Clinic). The genotype on a relapse test matches the original.

Reinfection means a new exposure to the virus after the first infection was fully cleared. It can happen at any time, months or years later, and it looks exactly like relapse on a simple RNA test. Specialists sometimes distinguish the two by checking whether the viral strain has changed. Because prior infection confers no immunity, the risk of reinfection is governed entirely by ongoing exposure, which is why people with continuing risk are offered periodic RNA testing after treatment (CDC).

Neither event is a moral failing, and neither closes the door on further treatment. Clinical guidance in most settings supports retreating people who are reinfected, on the straightforward logic that an untreated infection harms the person and can spread to others.

What you can do in practical terms is modest but real: know your own exposure risks honestly, keep any harm-reduction supports in place, and attend the follow-up tests you are offered even if you feel entirely well. If an RNA test is detectable after a clear SVR12, the question to ask your team is not “did the treatment fail” but “relapse or reinfection, and what does that mean for the next step.”

Is hep C terminal? What the evidence says about long-term outlook

People still type this question into search engines, often late at night, and the honest answer is no: hepatitis C is a treatable chronic infection, not a terminal diagnosis. The fear comes from an earlier era when treatment was long, harsh and often ineffective, and from the fact that untreated infection can, over decades, cause serious liver disease in some people.

The numbers help set the scale. The World Health Organization estimates that about 30% of people (within a range of 15% to 45%) clear the virus on their own within six months of infection, without any treatment. The remaining 55% to 85% develop chronic infection. Of those with chronic infection, roughly 15% to 30% go on to develop cirrhosis within 20 years. Cirrhosis in turn raises the risk of liver failure and liver cancer. Globally, WHO attributes around 242,000 deaths a year to hepatitis C, overwhelmingly from these late complications in people who were never diagnosed or treated.

Every step of that chain can be interrupted. Diagnosis is a blood test. Treatment is a short course of tablets. A sustained virologic response halts further viral damage and, over time, is associated with reduced inflammation and, in many people, partial reversal of scarring (Mayo Clinic, Cleveland Clinic). The residual risk that remains after treatment is concentrated in people who already had cirrhosis, which is precisely why they are offered continued surveillance.

None of this means the outlook is identical for everyone. Age at infection, alcohol use, other liver conditions, HIV or hepatitis B co-infection, and how advanced the scarring was at treatment all shape what comes next. What the evidence does support, firmly, is that the word “terminal” does not belong anywhere near a diagnosis that most people can clear with a few months of treatment.

Does an undetectable result mean your liver is back to normal?

Not automatically. The RNA test measures virus, not tissue. A liver that has carried an infection for twenty years may have accumulated fibrosis (the laying down of scar tissue in response to repeated inflammation), and in its advanced form, cirrhosis. Removing the cause of the inflammation stops the process; it does not instantly undo the result.

What happens next depends on where the liver started. Where scarring was mild, enzyme levels usually settle and the tissue has a reasonable capacity to remodel over months to years. Where cirrhosis was present, improvement is possible but slower and less complete, and the architecture of the organ may remain permanently altered (Mayo Clinic, Cleveland Clinic).

This is why the appointment that delivers your hepatitis C treatment results often includes, or is followed by, an assessment of the liver itself. Common tools include a blood panel scored for fibrosis, an ultrasound, and a non-invasive elastography scan (a device that measures liver stiffness through the skin, since stiffer tissue generally means more scarring). A liver biopsy is now rarely needed for this purpose.

Two practical consequences follow for people with established cirrhosis. First, surveillance for liver cancer continues indefinitely, because the risk is lowered by treatment but not removed. Second, the general liver-protection advice that applied before treatment still applies after it: limiting alcohol, maintaining a healthy weight, managing diabetes and blood pressure, and being vaccinated against hepatitis A and B if not already immune. Several of these are things a hepatitis C diagnosis may have pushed to the background; the clear result is a good moment to bring them forward.

Ask explicitly: what stage was my liver at before treatment, what does my team expect it to do now, and what follow-up does that imply. Those three answers tell you more about your future than the SVR line alone.

What people often get wrong about hepatitis C treatment results

Myth one: a positive antibody test after treatment means the virus is back. It does not. Antibodies persist for life and do not indicate current infection; only the RNA test does (CDC).

Myth two: feeling well is proof the treatment worked. Hepatitis C is typically silent whether it is active or cleared. Symptoms are a poor guide in both directions, and the follow-up blood test is the only reliable readout (WHO).

Myth three: once treated, you are immune. There is no lasting immunity after hepatitis C infection, and reinfection from a new exposure is entirely possible. The protective behaviors do not retire with the virus.

Myth four: an undetectable result means the liver is healed. The RNA test measures virus, not scar tissue. People with cirrhosis need ongoing monitoring even after a sustained virologic response (Mayo Clinic).

Myth five: a “detected, below limit of quantification” result at 12 weeks means failure. It means the assay found a trace that it could not count. Some of these are laboratory noise; some are early relapse. The correct response is a repeat test and a conversation, not despair.

Myth six: viral load reflects how sick you are. It does not. A high viral load before treatment says nothing reliable about the degree of liver damage; it mainly matters for choosing and monitoring treatment.

Myth seven: treatment only works once. Relapse after direct-acting antivirals is uncommon, and when it occurs there are usually alternative regimens. Reinfection can also be retreated. Neither outcome exhausts your options.

Myth eight: you can skip the 12-week test if you felt fine on the tablets. The end-of-treatment result is not the final answer; the post-treatment result is. Missing it leaves the central question unanswered, and a relapse found late is still a relapse.

Most of these misunderstandings trace back to one conflation: between a test for the virus and a test for the body’s reaction to it. Keep those two ideas separate and the rest of the report becomes much easier to read.

Questions to ask your care team

Appointments are short and the questions that matter tend to arrive in the car park afterward. Writing a few down beforehand changes the quality of the conversation. These are the ones that tend to earn their place.

About the test itself: On what date should my 12-week sample be drawn, and how will I receive the result? Will you also test at 24 weeks or later, and if so, why in my case? If the result reads “detected, not quantifiable,” what will you do next?

About the liver: What stage of fibrosis did I have before treatment, and how was it measured? Do you expect it to improve, and over what kind of timescale? Do I need ongoing scans or blood tests, how often, and who arranges them?

About the future: Am I being discharged from specialist care, or staying under review? What should my regular doctor know, and can you send a summary? Should I be vaccinated against hepatitis A or B, and have those checks been done?

About daily life: Is there any reason for me to limit alcohol more strictly than general advice suggests? Are there medicines, including over-the-counter products and supplements, I should avoid because of my liver? What is my personal risk of reinfection, and what testing does that warrant?

About other people: Do I need to tell anyone I have been treated, such as household members or past partners, and is there support for that conversation? Should people close to me be offered testing?

About records: Can the words “sustained virologic response” be added to my record so that future antibody results are read correctly? Could I have a printed copy of the RNA result?

You will not need all of these, and your team may raise some unprompted. The point is to leave the appointment with the plan in your own words, not just theirs, and to know exactly who to contact if something changes.

When to call your doctor

Most of the period after treatment is uneventful, and most concerns can wait for the scheduled review. A small number cannot. Contact your care team promptly, or seek urgent care, if you notice any of the following: yellowing of the skin or the whites of the eyes (jaundice), dark tea-colored urine or pale clay-colored stools, swelling of the abdomen or legs, vomiting blood or passing black tarry stools, new confusion, unusual drowsiness or difficulty staying awake, severe pain in the upper right abdomen, or a fever with worsening fatigue. These can signal liver inflammation or decompensation from any cause and warrant assessment the same day, regardless of what your most recent RNA test showed (NHS, MedlinePlus).

Call during ordinary hours, without waiting for the next appointment, if your 12-week sample has not been arranged and the date is approaching, if you receive a result you do not understand, if a laboratory report shows detectable RNA after a previous undetectable result, or if liver enzyme values on an unrelated blood test are flagged as high. The same applies if you have had a possible new exposure to blood, such as a shared needle or a needlestick, since testing for reinfection has its own timing.

Tell your team about any new medicine, including herbal and over-the-counter products, before starting it. Some can stress the liver or interact with other treatments you take, and a pharmacist or prescriber can check quickly.

Mental health belongs on this list too. A long infection, a treatment course and a three-month wait take a toll, and low mood or anxiety that lingers after a clear result is common enough to deserve attention rather than endurance. Your clinician can point you to support.

Every decision about retesting, retreatment or further investigation sits with the team who knows your history. This article explains the map; they are the ones holding your coordinates.

Frequently asked questions

How long does hep C treatment take with current tablets?

Most courses of direct-acting antiviral tablets last 8 to 12 weeks, taken once a day, according to the NHS; some run up to 24 weeks when the liver is heavily scarred or earlier treatment did not clear the virus. The prescribing team chooses the length based on viral genotype, liver condition and treatment history. The follow-up RNA test is scheduled about 12 weeks after the last tablet.

How contagious is hep C in everyday household contact?

Hepatitis C spreads only through blood-to-blood contact. It is not passed by hugging, kissing, sharing food, utensils or bathrooms, or by breastfeeding unless nipples are cracked and bleeding, according to the CDC. Household risk comes from items that can carry blood, such as razors, toothbrushes and nail clippers. Once your RNA test is undetectable after treatment, there is no virus in your blood to transmit.

Is hep C terminal if it goes untreated for years?

No. Hepatitis C is a treatable chronic infection, not a terminal illness. Left untreated, the World Health Organization estimates that 15% to 30% of people with chronic infection develop cirrhosis within 20 years, which raises the risk of liver failure and cancer. A short course of tablets stops ongoing viral damage, and people with established cirrhosis are offered continued monitoring to catch complications early.

What is the main cause of hep C?

The only cause is the hepatitis C virus, which enters the body when infected blood reaches the bloodstream. In the United States, the CDC identifies sharing equipment to inject drugs as the most common route. Globally, unsafe medical injections, unsterilized equipment and unscreened transfusions also contribute, per WHO. Transmission from a pregnant parent to the baby occurs in roughly 6% of affected births, according to the CDC.

Why does my hepatitis c antibody test after treatment still say positive?

Because antibodies are the immune system’s memory of an infection, not the infection itself. Once made, hepatitis C antibodies usually persist for life, whether the virus was cleared by treatment or on its own. A positive antibody result after treatment is expected and does not mean relapse. The RNA test, which looks for the virus’s genetic material, is the only one that shows whether virus is present.

What does "detected, below limit of quantification" mean on my report?

It means the laboratory found a trace of viral genetic material too small to count. At 12 weeks after treatment this sits in a gray zone: it can reflect laboratory noise or the earliest stage of relapse. Clinicians usually respond by repeating the test, sometimes with a more sensitive assay, rather than drawing a conclusion. It is a prompt for a conversation with your team, not a verdict.

Can hep c reinfection after treatment really happen, and how would I know?

Yes. Hepatitis C infection leaves no protective immunity, so a new exposure to infected blood can cause a second infection at any time. On a simple RNA test it looks identical to relapse, though the viral strain may differ. You would not feel it; the infection is usually silent. People with ongoing exposure risk are therefore offered periodic RNA testing, and reinfection can be treated again.

Do I need any more follow-up once my SVR12 result is undetectable?

It depends on your liver. People with little or no scarring are often discharged from specialist care after SVR12, with a summary sent to their regular doctor. People with cirrhosis continue long-term surveillance for liver cancer, typically with imaging and blood tests, because the risk is reduced by treatment but not removed, as Mayo Clinic notes. Your team will tell you which plan applies.

Will my liver enzymes go back to normal after the virus is cleared?

For many people, ALT and AST levels fall toward the normal range within weeks of the virus becoming undetectable, because the main source of inflammation has gone. If they stay raised after an undetectable RNA result, that usually points to another cause, such as alcohol, fatty liver disease or a medication effect, and is worth investigating. Persistently high enzymes are not a sign that hepatitis C has returned.

What happens if the 12-week hepatitis C treatment result is still detectable?

The team will first confirm the result, then work out whether it represents relapse of the original infection or a new infection, sometimes by comparing viral strains. Relapse after direct-acting antivirals is uncommon; when it occurs, resistance testing often guides a different regimen. Reinfection can also be retreated. Neither outcome exhausts your options, and decisions about next steps sit with the prescribing clinician.

References

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.

Dr. Şule Eren
Dr. Şule Eren, MD
Author
View profile →
Published November 18, 2026
Keep Reading

More from the Blog

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.